HIV Infections Clinical Trial
Official title:
The Effect of Efavirenz and Nelfinavir on the Pharmacokinetics of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors
The purpose of this study is to find out whether certain anti-HIV drugs (efavirenz [EFV] and
nelfinavir [NFV]) affect the amount of certain fat-lowering drugs (atorvastatin,
pravastatin, and simvastatin) in the blood.
Protease inhibitors (PIs), a type of anti-HIV drug, are known to cause increased lipids
(fats) in the blood of HIV-infected patients. EFV also is known to increase blood fats.
HIV-infected patients who take PIs and/or EFV may need to take fat-lowering drugs to correct
this problem. So it is important to look at possible drug interactions when these drugs are
taken together. This study will see if taking EFV or NFV, a protease inhibitor, affects the
blood level of simvastatin, atorvastatin, or pravastatin (all fat-lowering drugs). To obtain
results more quickly, the study population will be healthy HIV-negative volunteers.
Abnormalities in lipid metabolism are a recognized side effect of protease inhibitor (PI)
therapy in HIV-infected patients. EFV also is known to increase plasma cholesterol. In an
attempt to normalize serum lipids in HIV-infected patients on PIs and/or EFV,
Hydroxymethylglutaryl Coenzyme A (HMG-CoA) reductase inhibitors (also known as statins) may
be prescribed. Therefore, it is important to study how PIs and EFV affect the PK of
concurrently-administered statins. Many of the statins utilize the cytochrome P450 (CYP) 3A4
enzyme for metabolism. In addition, atorvastatin and simvastatin have active metabolites,
generated via CYP3A4, that contribute to the drugs' lipid-lowering activity and probably to
their toxicity. Pravastatin is not metabolized by CYP3A4 but is inactivated by conjugation,
non-CYP3A4-induced hydroxylation, and renal excretion. NFV, the most commonly used PI, is an
inhibitor of CYP3A4 and an inducer of other CYPs and conjugative pathways. EFV is a mixed
CYP3A4 inhibitor and inducer. This study examines the effect of NFV on the PK of pravastatin
and the effect of EFV on the PK of simvastatin, atorvastatin, and pravastatin. As EFV with
pravastatin is expected to be a common drug combination during the treatment of HIV
infection, it should be explored further, even though drug interactions are not expected. To
expedite this study, the study population is comprised of healthy control volunteers.
Volunteers are assigned to 1 of 4 groups. Volunteers in Groups A, B, and C take a statin
(simvastatin, atorvastatin, or pravastatin, respectively) on Days 0 to 3. After Day 3, the
statin is stopped and EFV is begun. Volunteers take EFV until Day 14 and the statin and EFV
together from Days 15 to 18. Volunteers in Group D take pravastatin on Days 0 to 3, NFV on
Days 4 to 12, and pravastatin and NFV together on Days 13 to 16. Fasting lipid profiles are
performed on Days 0, 4, 15, and 19 for Groups A, B, and C, and on Days 0, 3, 13, and 16 for
Group D. PK sampling is performed on Days 3, 14, and 18 for Groups A, B, and C (requiring an
overnight stay), and on Days 3 and 16 for Group D. Volunteers receive monetary compensation
for participation in this study.
;
Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |